Trial record 10 of 135 for: Drug | "Connective Tissue Disease" | "Abatacept"
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00048581|
Recruitment Status : Completed
First Posted : November 13, 2002
Results First Posted : June 23, 2011
Last Update Posted : November 21, 2011
Information provided by (Responsible Party):
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment|
|Pre-assignment Details||738 participants were enrolled and 393 participants were randomized. Two participants were randomized in error and were not treated.|